NCT06937203View on ClinicalTrials.gov

Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
ObesityDiabetes Mellitus, Type 2
Interventions
DRUG

ARO-ALK7

SC injection

DRUG

Placebo

calculated volume to match active treatment by SC injection

Trial Locations (1)

1010

RECRUITING

Research Site, Auckland

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY

NCT06937203 - Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter